Alnylam Netherlands

Patisiran (ONPATTRO) is a small-molecule therapeutic developed by Alnylam Netherlands B.V. for the treatment of amyloidosis. The program, identified as ALN-TTR02-006, has completed Phase 3 clinical development. Patisiran sodium is administered intravenously and has achieved regulatory approval in multiple jurisdictions, including the United States (NDA 210922), European Union (EMEA/H/C/004699, authorized 24 March 2025), and Australia (listed 1 August 2024). The drug is marketed under the brand name ONPATTRO. As of the latest milestone dated 6 December 2023, the program status is listed as completed. The sponsor strategy appears focused on establishing market presence across major regulatory regions, with approvals now secured in the US, EU, and Australia. Specific details regarding mechanism of action, molecular target, and detailed clinical efficacy data are not yet disclosed in the available intelligence.

Amyloidosis represents a significant unmet medical need, particularly in transthyretin (TTR)-mediated disease, which can present as hereditary or wild-type forms with substantial morbidity and mortality. The approval of patisiran expands the therapeutic armamentarium for this rare but serious condition. Market relevance is underscored by the rarity of amyloidosis, which typically affects a limited patient population but with high disease burden and limited treatment options historically available. Patisiran's intravenous route and small-molecule classification position it within a growing competitive landscape that includes other approved therapies such as AMVUTTRA (Lacuna Pharma) and VYNDAMAX (Pfizer). The commercial significance is tied to orphan drug designation potential, premium pricing typical of rare disease therapeutics, and the global expansion of approvals across the US, EU, and Australia. Patient population characteristics—including disease severity, progression rates, and geographic distribution—remain key factors in determining peak sales potential and market penetration. The competitive environment suggests that differentiation may depend on efficacy, safety profile, dosing convenience, and real-world clinical outcomes rather than first-mover advantage alone.

Drug Class: Small-molecule therapeutic for rare disease (amyloidosis).

Modality: Small molecule.

Route of Administration: Intravenous.

Therapeutic Classification: Nervous system agent (ATC N07).

Brand Name: ONPATTRO.

Active Ingredient: Patisiran sodium (INN).

Mechanism of Action: Not yet disclosed.

Molecular Target: Not yet disclosed.

Related Therapies: AMVUTTRA (Lacuna Pharma), VYNDAMAX (Pfizer), and other nervous system agents approved for amyloidosis or related neurological conditions.

First Approval: United States (FDA, NDA 210922); European Union (EMA, 24 March 2025); Australia (TGA, 1 August 2024).

Patent Status: Not yet disclosed.

United States (FDA): Patisiran sodium approved under NDA 210922; sponsor listed as ALNYLAM PHARMS INC. Specific approval date not yet disclosed.

European Union (EMA): Patisiran authorized on 24 March 2025 under EMEA/H/C/004699. Marketing Authorization Holder: Alnylam Netherlands B.V.

Australia (TGA): Patisiran listed on Australian Register of Therapeutic Goods on 1 August 2024. Sponsor: MEDISON PHARMA AUSTRALIA PTY LIMITED. PBS codes: 14264R, 14296K.

Japan (PMDA): Regulatory status not yet disclosed.

China (NMPA): Regulatory status not yet disclosed.

Other Regions: No additional regulatory approvals documented in the available intelligence.

Strategic Implications: Alnylam's approval trajectory across the US, EU, and Australia within a compressed timeframe (August 2024 to March 2025) suggests coordinated regulatory submissions and successful clinical evidence packages. The completion of Phase 3 development and subsequent approvals indicate a mature program with sufficient efficacy and safety data to support market authorization. The small-molecule modality and intravenous route may offer advantages in terms of manufacturing scalability and bioavailability compared to alternative modalities, though patient convenience may be a consideration relative to oral competitors.

Competitive Implications: Patisiran enters a market with established competitors (VYNDAMAX, AMVUTTRA) and must differentiate on clinical efficacy, safety profile, and real-world outcomes. The approval in multiple major markets simultaneously positions Alnylam for rapid market penetration. However, the lack of disclosed mechanism of action and specific trial endpoints limits ability to assess clinical superiority at this stage. Competitive positioning will likely depend on head-to-head trial data, if available, and post-marketing surveillance outcomes.

Future Catalysts: Expected catalysts include publication of Phase 3 trial results in peer-reviewed journals, real-world evidence generation, potential label expansions to additional amyloidosis subtypes or patient populations, and market share data as the drug gains adoption. Additional regulatory approvals in Japan (PMDA) and China (NMPA) would represent significant commercial milestones.

Expected Milestones: No specific next milestones are disclosed in the available intelligence. Potential future events may include expanded indication approvals, combination therapy studies, or geographic expansion to additional markets.